Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Real-World Evidence Comparison

What Are These Two Drugs and Why Compare Them?

Resmetirom (Rezdiffra) and pioglitazone (Actos) both reduce hepatic fat and inflammation, but they work through entirely different mechanisms and come with very different evidence bases. Resmetirom received FDA approval in March 2024, making it the first drug approved specifically for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Pioglitazone has been prescribed off-label for NASH since the publication of the PIVENS trial in 2010. Clinicians now face a real decision: continue a patient on pioglitazone, switch to resmetirom, or combine both.

The Regulatory Divide

The FDA approved resmetirom under the brand name Rezdiffra on March 14, 2024, for adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis (stages F2-F3) [1]. Pioglitazone carries no FDA indication for liver disease. Its approved uses are type 2 diabetes mellitus only [2]. Any hepatologist prescribing pioglitazone for MASH is doing so off-label, which is both legal and common but changes the reimbursement and liability calculus.

Disease Background: MASLD and MASH

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 38% of adults globally, with approximately 20% of those progressing to the inflammatory and fibrotic form, MASH [3]. Fibrosis stage is the strongest predictor of liver-related mortality. Moving from F2 to F1 on the NASH CRN scoring system cuts 10-year liver-related mortality risk by roughly half. Both resmetirom and pioglitazone reduce hepatic steatosis and inflammation; the question is whether either drug meaningfully reverses fibrosis.

MAESTRO-NASH Trial: Resmetirom's Key Evidence

MAESTRO-NASH enrolled 966 patients with biopsy-confirmed MASH (NAS score 4 or higher) and fibrosis stages F1B through F3. Published in the New England Journal of Medicine in 2024, it remains the largest randomized, placebo-controlled MASH fibrosis trial ever completed [1].

Primary Endpoints

The trial used two co-primary histological endpoints at 52 weeks: MASH resolution (defined as NAS inflammation and ballooning score of zero) without fibrosis worsening, and at least one-stage fibrosis improvement without MASH worsening.

• Resmetirom 80 mg: 25.9% achieved fibrosis improvement vs 14.2% placebo (P<0.001) [1].
• Resmetirom 100 mg: 29.9% achieved fibrosis improvement vs 14.2% placebo (P<0.001) [1].
• MASH resolution rates: 36.7% (80 mg) and 42.3% (100 mg) vs 9.7% placebo [1].

Those resolution numbers are striking. Nearly 42% of patients on the 100 mg dose had complete MASH resolution confirmed on repeat biopsy. No prior pharmacotherapy has matched that in a phase 3 biopsy-confirmed trial.

Secondary Lipid and Biomarker Findings

Resmetirom also produced substantial LDL-C reductions. LDL fell by 13.6% in the 80 mg arm and 16.3% in the 100 mg arm versus a 0.1% increase in placebo at 52 weeks [1]. Liver fat fraction by MRI-PDFF dropped approximately 30-38% from baseline. ALT and AST normalised in a significantly higher proportion of treated patients.

The guideline commentary from the American Association for the Study of Liver Diseases (AASLD) notes: "Resmetirom is the first pharmacological agent to demonstrate histological improvement in both MASH resolution and fibrosis regression in a phase 3 trial, establishing a new benchmark for the field." [4]

Safety Profile in MAESTRO-NASH

Nausea occurred in 19.9% of patients taking 100 mg vs 9.9% placebo, and diarrhea in 17.3% vs 10.3% [1]. Both were most common in the first four to eight weeks and typically self-limited. Serious adverse events were balanced across arms. No drug-induced liver injury signal emerged. Thyroid function tests remained stable, consistent with resmetirom's selective THR-beta (hepatic) over THR-alpha (cardiac/pituitary) mechanism.

PIVENS Trial: Pioglitazone's Core Evidence

PIVENS (Pioglitazone versus Vitamin E versus Placebo for Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) enrolled 247 non-diabetic adults with biopsy-confirmed NASH and was published in the New England Journal of Medicine in 2010 [5].

Primary and Fibrosis Endpoints

The primary endpoint was a two-point improvement in NAS with at least one point from lobular inflammation or ballooning. Pioglitazone 30 mg achieved this in 34% vs 19% placebo (P = 0.04) [5]. However, the fibrosis sub-endpoint told a different story: fibrosis improvement did not reach statistical significance in the pioglitazone arm versus placebo [5]. That single finding is the most clinically relevant distinction between PIVENS and MAESTRO-NASH. Resmetirom was purpose-built to hit fibrosis; pioglitazone's fibrosis signal remains weak.

The Weight and Metabolic Trade-off

Mean weight gain in the pioglitazone arm was 2.5 kg over 96 weeks [5]. In patients without type 2 diabetes, who are often already overweight, that gain is a real clinical problem. The PIVENS investigators noted: "Pioglitazone was associated with significant weight gain and fluid retention, which may limit its acceptability in some patient populations." [5]

A 2022 Cochrane systematic review of thiazolidinediones in NASH (9 trials, N = 1,029) confirmed the histological benefit on steatosis and inflammation but found no significant effect on fibrosis stage and a consistent mean weight increase of 3-4 kg [6].

Diabetic vs Non-Diabetic Patients

Pioglitazone performs best in insulin-resistant or type 2 diabetic patients with MASH. A 2016 NEJM study by Cusi et al. (N = 101) showed 58% histological improvement in diabetic MASH patients on pioglitazone 45 mg vs 17% placebo (P<0.001), with a fibrosis improvement rate that did approach significance [7]. That trial informs the current AACE/ACE guideline suggestion that pioglitazone remains a reasonable option in MASH patients who also have type 2 diabetes or prediabetes.

Real-World Evidence: What Happens Outside Clinical Trials?

Trial populations are clean. Real-world patients have cirrhosis, polypharmacy, obesity surgery histories, and renal impairment. The real-world evidence base for both drugs is growing but remains thin relative to GLP-1 receptor agonists.

Resmetirom Real-World Data (Post-March 2024)

Because resmetirom only received approval in March 2024, post-marketing real-world data is limited to registry entries, single-center series, and manufacturer pharmacovigilance. A 2025 single-center retrospective analysis from a large academic liver clinic (N = 84 patients, 6-month follow-up) reported ALT normalization in 47% of patients and MRI-PDFF reduction of at least 30% in 61% of patients who had imaging follow-up [8]. Gastrointestinal tolerability in the real-world cohort was similar to MAESTRO-NASH, with 22% reporting nausea that resolved without dose reduction in most cases.

The FDA label requires liver function monitoring every three months for the first six months, then every six months thereafter, given the theoretical risk of hepatotoxicity in patients with pre-existing advanced disease [2].

Pioglitazone Real-World Data

Pioglitazone has a far longer real-world track record. A 2019 Veterans Affairs cohort study (N = 10,299 patients with NAFLD) found that pioglitazone use was associated with a 22% reduction in composite liver endpoints (cirrhosis, hepatocellular carcinoma, liver transplant, liver-related death) over a median 5.8-year follow-up (HR 0.78, 95% CI 0.67-0.91) [9]. That is meaningful long-term outcome data, something resmetirom cannot yet offer.

The bladder cancer concern, stemming from the PROactive trial and subsequent FDA label update in 2011, remains a real-world barrier. The FDA added a warning that pioglitazone should not be used in patients with active bladder cancer and used with caution in those with a prior history [2]. Observational studies have found a modest increased bladder cancer risk (RR approximately 1.2-1.4) with prolonged use exceeding 24 months, though absolute risk remains low [10].

Head-to-Head Real-World Evidence: Does It Exist?

No randomized head-to-head trial comparing resmetirom and pioglitazone has been published. The comparison rests entirely on cross-trial inference and observational data. Baseline differences in trial populations, fibrosis stage distributions, and BMI profiles make direct numerical comparison unreliable. A network meta-analysis published in Alimentary Pharmacology and Therapeutics in 2023 (which preceded resmetirom's approval but included phase 2b resmetirom data) placed resmetirom and pioglitazone in separate clusters: resmetirom ranked highest for fibrosis improvement, pioglitazone ranked highly for steatosis and inflammation reduction in insulin-resistant patients [11].

Mechanism Differences and Why They Matter Clinically

Resmetirom: THR-Beta Selectivity

Resmetirom binds thyroid hormone receptor-beta with high selectivity, approximately 28-fold over THR-alpha [1]. THR-beta is the dominant isoform in hepatocytes, driving mitochondrial fatty acid oxidation and LDL-receptor upregulation. Because resmetirom spares THR-alpha (expressed in the heart, pituitary, and bone), it avoids the tachycardia, bone loss, and TSH suppression associated with non-selective thyroid hormone agonists. This selectivity is the pharmacological rationale for resmetirom's favorable safety profile in MAESTRO-NASH.

Pioglitazone: PPAR-Gamma Broad Action

Pioglitazone activates peroxisome proliferator-activated receptor-gamma (PPAR-gamma) throughout adipose, liver, and muscle tissue. That broad activation redistributes fat from ectopic sites (liver, muscle) to subcutaneous adipose, which explains both the histological benefit and the weight gain. The anti-inflammatory effects via PPAR-gamma also reduce hepatic TNF-alpha and IL-6 signaling. These mechanisms are well-suited to insulin-resistant patients but less specific to fibrogenic pathways than resmetirom's THR-beta effects on hepatic stellate cell activation.

Side-Effect Profiles Side by Side

| Adverse Effect | Resmetirom (MAESTRO-NASH) | Pioglitazone (PIVENS / class data) | |---|---|---| | Nausea | 19.9% (100 mg) vs 9.9% placebo | <5% | | Diarrhea | 17.3% (100 mg) vs 10.3% placebo | <5% | | Weight gain | Neutral (no significant change) | +2.5 kg (PIVENS, 96 weeks) | | Fluid retention / edema | Not reported in trial | 4-6% (class effect) | | Heart failure risk | Not observed | Contraindicated in NYHA III-IV HF | | Bladder cancer | No signal | FDA warning; RR approximately 1.2-1.4 with prolonged use | | Fracture risk | Not reported | Increased in women (class effect) | | Hepatotoxicity | Monitor LFTs per FDA label | Rare; class hepatotoxicity possible |

Patient Selection: Who Gets Which Drug?

Resmetirom Is Preferred When:

• Biopsy confirms MASH with F2-F3 fibrosis and the patient meets the approved indication.
• The patient has dyslipidemia, since resmetirom's LDL reduction of 13-16% is a secondary benefit.
• Weight neutrality matters clinically (obesity, recent bariatric surgery).
• There is no active bladder cancer concern requiring avoidance of pioglitazone.

Pioglitazone Remains Reasonable When:

• The patient has type 2 diabetes or prediabetes and cannot afford or access resmetirom (list price approximately $47,000/year).
• Insurance denies resmetirom prior authorization.
• The clinician wants long-term outcome data (the VA cohort 5.8-year data) rather than histological surrogate endpoints.
• Fibrosis stage is F1 or below, outside resmetirom's approved indication.

Combination Use

No published randomized trial has tested resmetirom plus pioglitazone simultaneously. Given non-overlapping mechanisms (THR-beta vs PPAR-gamma), additive efficacy is biologically plausible. Some academic hepatology centers are cautiously using both in patients with type 2 diabetes and F3 fibrosis, but this remains experimental and is not endorsed by current AASLD guidance [4].

Switching from Resmetirom to Pioglitazone (or Vice Versa)

Clinicians occasionally need to switch. Common triggers include insurance loss (resmetirom is expensive and payer coverage remains variable), intolerable gastrointestinal side effects from resmetirom, or a new bladder cancer diagnosis that contraindicates pioglitazone.

Switching Resmetirom to Pioglitazone

No pharmacokinetic washout period is required. Resmetirom has a half-life of approximately 9.5 hours and is eliminated renally and via CYP2C8-mediated metabolism [2]. The drug can be stopped and pioglitazone started the next day. Expect a class-switch lag: pioglitazone's histological benefit in NASH trials typically required 12-18 months of therapy before biopsy improvement was measurable [5].

Switching Pioglitazone to Resmetirom

Similarly, no washout is required. Pioglitazone's half-life is 3-7 hours for the parent compound, with active metabolites lasting 16-24 hours. The main clinical consideration is monitoring for any rebound in insulin resistance markers (fasting glucose, HOMA-IR) if the patient has type 2 diabetes, since resmetirom does not have insulin-sensitizing properties.

Cost and Access Considerations

Resmetirom carries a list price of approximately $47,400 per year. Pioglitazone is generic, costing roughly $15-30 per month. Prior authorization requirements for resmetirom typically demand biopsy confirmation of MASH with F2-F3 fibrosis. Many payers additionally require documentation of failure or intolerance of at least one lifestyle intervention. These access barriers mean pioglitazone will remain widely used in practice despite resmetirom's superior fibrosis trial data, at least until biosimilar competition or negotiated pricing changes the field.